Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 9INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × semaglutide × Clear all
NCT04572165 2024-01-02

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Novo Nordisk A/S

Unknown
600,000 enrolled

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡